midodrine has been researched along with Hypovolemia in 6 studies
Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.
Hypovolemia: An abnormally low volume of blood circulating through the body. It may result in hypovolemic shock (see SHOCK).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fifty patients with cirrhosis and tense refractory ascites were randomly assigned to be treated with either midodrine (n=25) (12." | 5.19 | Comparison of midodrine and albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients: a randomized pilot study. ( ElBaz, AA; Hamdy, H; Hassan, A; Hassanin, O, 2014) |
| "Twenty-four patients with cirrhosis and ascites were randomly assigned to be treated with either midodrine (n=11) (12." | 5.13 | Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study. ( Appenrodt, B; Grünhage, F; Heller, J; Lammert, F; Rabe, C; Sauerbruch, T; Schepke, M; Trebicka, J; Wolf, A, 2008) |
| "Midodrine therapy was cheaper than albumin therapy." | 2.73 | Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study. ( Bhalla, A; Chawla, D; Dheerendra, PC; Mahi, SK; Nain, CK; Sharma, N; Singh, B; Singh, V, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Joseph, A | 1 |
| Wanono, R | 1 |
| Flamant, M | 1 |
| Vidal-Petiot, E | 1 |
| Hamdy, H | 1 |
| ElBaz, AA | 2 |
| Hassan, A | 1 |
| Hassanin, O | 1 |
| Bai, M | 1 |
| Han, G | 1 |
| Singh, V | 1 |
| Dheerendra, PC | 1 |
| Singh, B | 1 |
| Nain, CK | 1 |
| Chawla, D | 1 |
| Sharma, N | 1 |
| Bhalla, A | 1 |
| Mahi, SK | 1 |
| Appenrodt, B | 1 |
| Wolf, A | 1 |
| Grünhage, F | 1 |
| Trebicka, J | 1 |
| Schepke, M | 1 |
| Rabe, C | 1 |
| Lammert, F | 1 |
| Sauerbruch, T | 1 |
| Heller, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Midodrine Versus Albumin During Large-volume Paracentesis and Its Effect on Paracentesis Induced Circulatory Disturbance in Patients With Acute on Chronic Liver Failure - A Randomized Controlled Trial[NCT05240391] | Phase 3 | 50 participants (Actual) | Interventional | 2021-02-20 | Completed | ||
| Vasoconstrictors as Alternatives to Albumin After Large Volume Paracentesis in Cirrhosis[NCT00108355] | Phase 4 | 29 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| Efficacy of Terlipressin in Cirrhotic Patients With Recidivation Ascites Treated With Paracentesis and Albumin. A Multi-center Randomized Controlled Study[NCT00986817] | Phase 3 | 82 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Defined as an increase in Plasma Renin Activity (PRA) by >50% from baseline to a level > 4 ng/mL/h at post-paracentesis day (NCT00108355)
Timeframe: 6 days after paracentesis
| Intervention | participants (Number) |
|---|---|
| Albumin (Control Group) | 2 |
| Vasoconstrictor (Treatment Group) | 2 |
Comparison between Albumin (Control group) and Vasoconstrictor (Treatment group) (NCT00108355)
Timeframe: Variable depending on the patient, average 10 days
| Intervention | days (Median) |
|---|---|
| Albumin (Control Group) | 10 |
| Vasoconstrictor (Treatment Group) | 8 |
1 review available for midodrine and Hypovolemia
| Article | Year |
|---|---|
Orthostatic hypotension: A review.
Topics: Aging; Anti-Inflammatory Agents; Drug Therapy, Combination; Fludrocortisone; Humans; Hypotension, Or | 2017 |
3 trials available for midodrine and Hypovolemia
| Article | Year |
|---|---|
Comparison of midodrine and albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients: a randomized pilot study.
Topics: Albumins; Aldosterone; Ascites; Creatinine; Female; Humans; Hypovolemia; Liver Cirrhosis; Male; Midd | 2014 |
Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study.
Topics: Adult; Ascites; Female; Humans; Hypovolemia; Liver Cirrhosis; Male; Middle Aged; Midodrine; Paracent | 2008 |
Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study.
Topics: Adrenergic alpha-Agonists; Albumins; Aldosterone; Ascites; Double-Blind Method; Female; Humans; Hypo | 2008 |
Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study.
Topics: Adrenergic alpha-Agonists; Albumins; Aldosterone; Ascites; Double-Blind Method; Female; Humans; Hypo | 2008 |
Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study.
Topics: Adrenergic alpha-Agonists; Albumins; Aldosterone; Ascites; Double-Blind Method; Female; Humans; Hypo | 2008 |
Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study.
Topics: Adrenergic alpha-Agonists; Albumins; Aldosterone; Ascites; Double-Blind Method; Female; Humans; Hypo | 2008 |
2 other studies available for midodrine and Hypovolemia
| Article | Year |
|---|---|
Midodrine for paracentesis-induced circulatory dysfunction.
Topics: Albumins; Ascites; Female; Humans; Hypovolemia; Male; Midodrine; Paracentesis; Vasoconstrictor Agent | 2014 |
In response.
Topics: Albumins; Ascites; Female; Humans; Hypovolemia; Male; Midodrine; Paracentesis; Vasoconstrictor Agent | 2014 |